Now I have all the information I need. Let me construct the final consolidated review.

Since the calibration search is unavailable, I will calibrate based on my assessment of the paper against ICLR standards, considering comparable papers I know from the clinical NLP and benchmarking literature. The paper's core strengths and weaknesses are clear from direct reading.

Let me finalize the review with careful attention to which weaknesses to retain and which to filter.

---

## Summary

This paper evaluates small language models (SLMs, 1–3B parameters) and small vision-language models (SVLMs) against larger, medically-adapted counterparts (7–9B) on clinical text summarization (MeQSum) and radiology report generation (MIMIC-CXR). The paper introduces a "Collapse Analysis" framework to identify a safety threshold at ~1B parameters, and finds that after LoRA fine-tuning, small LMs can match or exceed larger medical LMs on text metrics, while small VLMs continue to lag behind large VLMs on radiology report generation.

## Strengths

1. **Identification of a quantitative "safety collapse" threshold**: Table 3 documents a sharp, non-linear degradation below ~1B parameters — hallucination rates jump from 2–3% (SmolLM2-1.7B, Gemma-3-1B) to 18.3% (SmolLM2-360M) and 75% (Gemma-3-270M), while Task Adherence and Concept Recall drop in concert across two model families. This pinpoints a specific parameter scale where safety-critical failures emerge, which is a practically useful finding for deployment decisions.

2. **Contrastive finding across modalities**: The paper establishes a non-obvious asymmetry: after LoRA fine-tuning, small LMs (1B) can match or exceed large LMs (7–8B) on text summarization, but small VLMs continue to lag behind large VLMs on radiology report generation even after fine-tuning. This differential result is actionable for resource-allocation decisions in clinical NLP.

3. **Systematic multi-family evaluation**: The paper evaluates models across SmolLM2, Gemma-3, LLaMA-3.2, Florence 2, and Qwen 2.5-VL against BioMistral, Med-LLaMA, OpenBioLLM, Med-Flamingo, and LLaVA-Med — broader coverage than most prior work that tests only one or two model families.

4. **Treatment of prompt sensitivity as an experimental variable**: The paper averages across five prompt templates to mitigate sensitivity and treats prompt design as an experimental variable rather than fixing a single template (line 110), which is good methodological practice.

## Weaknesses

### Major

1. **Confounded comparison between small and large LMs**: The paper's central claim — that "after LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (line 231) — compares LoRA-fine-tuned small models against large models evaluated **only with in-context learning (ICL)**. Figure 3 and the accompanying table (lines 158–183) show large models (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) with scores reported only under the "ICL" column; their "LoRA" columns contain dashes. The paper states LoRA was applied "to each small LLM" (line 120) and never states that the large models were also LoRA-tuned. This means every claimed advantage of small models over large ones simultaneously reflects the advantage of *fine-tuning* over *zero-shot ICL*. The title asks "Is model size a barrier to quality?" but the experiment never holds adaptation method constant while varying size. The paper would need at minimum a 2×2 comparison (small+ICL vs. large+ICL, small+LoRA vs. large+LoRA) to support its headline claim.

2. **Collapse Analysis metrics are entirely undefined**: The paper introduces Task Adherence, Hallucination Rate, Clinical Concept Recall, Prompt Robustness, and a composite Readiness Score as a core claimed contribution (bullet 2 in the introduction, lines 24–26, and Table 3, lines 124–132). However, the paper never defines how **any** of these metrics are computed — no annotation protocol, no description of automated or human evaluation, no inter-annotator agreement, no definition of what constitutes a "hallucination" in this context, no formula for the composite Readiness Score. Without this information, the "safety collapse" finding — arguably the paper's most interesting result — is unreproducible and unverifiable.

3. **Same confound in VLM comparison**: Table 4 compares fine-tuned small VLMs (Florence 2, Qwen 2.5-VL) against large VLMs (Med-Flamingo, LLaVA-Med). The paper describes fine-tuning for the small VLMs (lines 199–206) but never states whether the large VLMs were also fine-tuned on the same 10K MIMIC-CXR pairs or evaluated zero-shot. If the large VLMs were not fine-tuned, the same confound applies, and the conclusion that "small VLMs continue to lag behind" may reflect an adaptation gap rather than a size gap.

### Minor

1. **No error bars, confidence intervals, or statistical testing**: All results (Tables 2, 3, 4; Figure 3) report point estimates on a test set of 250 samples. Without confidence intervals or significance tests, the reader cannot assess whether observed differences (e.g., SmolLM2's BERTScore of 0.9007 vs. BioMistral's 0.8857) are meaningful or within noise range. This is especially relevant for the safety-collapse thresholds, which are drawn from single data points per model size.

2. **Narrow parameter range for the "large" category**: The "large" LMs are 7–8B parameters — barely an order of magnitude above the "small" models (1–1.7B). The paper motivates the problem by discussing costs and barriers of models like MedGemini and MedPaLM2 (Introduction, lines 13–15) but never evaluates models in the 70B+ range. Conclusions about "model scale" are drawn from a narrow slice of the parameter spectrum. (The limitations section partially acknowledges this at lines 268–270.)

### Trivial

None.

## Nice-to-Haves

- Clarify whether the large VLMs (Med-Flamingo, LLaVA-Med) in Table 4 were fine-tuned on MIMIC-CXR or evaluated zero-shot.
- Adding bootstrap confidence intervals or significance tests would strengthen confidence in reported differences, especially for the safety-collapse thresholds.

## Removed Points

These points were filtered from the inputs, retained for reference:

- *Critic's claim that zero-shot results "contradict the paper's overall framing"* — Removed because the paper does not claim small models beat large ones in zero-shot; the zero-shot results are presented as a baseline, and the paper's claims are about fine-tuned small models.
- *Critic's claim about broken reference "Table ??"* — Removed as a PDF-extraction artifact, not an author error.
- *Strength Finder's generic statements about the paper addressing an important problem* — Removed as too generic and lacking specific evidence.
- *Critic's claim that the confound is fatal and invalidates everything* — Modified: it remains a major weakness, but the safety collapse analysis (Table 3) does not depend on the cross-model comparison, so it stands independently as a potentially salvageable contribution.

## Novel Insights

The two reviewers converge on the paper's interesting empirical observations (safety collapse at sub-1B, asymmetry between LMs and VLMs) but diverge sharply on severity. The harsh critic correctly identifies the central confound (model size × adaptation method) and the undefined metrics as structural problems, while the strength finder correctly highlights the practically useful safety-collapse finding. The key insight from synthesizing both is that the safety-collapse finding is the paper's strongest contribution and does **not** depend on the confounded large-vs-small comparison — it is purely an intra-family analysis of small models across scales. The confound mainly affects the paper's broader claims about "small beating large."

## Suggestions

1. **Define all Collapse Analysis metrics explicitly**: Provide formulas, annotation protocols, and if automated, describe the pipeline. Without this, the safety collapse finding cannot be verified or used by the community.
2. **Deconfound the size vs. adaptation comparison**: Either (a) run LoRA on the large LMs as well, or (b) clearly reframe all claims as "LoRA-tuned small LMs match/exceed ICL-only large LMs" rather than making blanket statements about model size.
3. **Clarify the VLM evaluation protocol**: State explicitly whether Med-Flamingo and LLaVA-Med were fine-tuned or evaluated zero-shot in Table 4.
4. **Add confidence intervals or bootstrapped estimates** for key results, particularly around the safety-collapse thresholds.
5. **Reframe the title and claims** to more accurately reflect the comparison being made and the actual parameter range studied (1–8B, not 1B vs. 70B+).

## Score and Decision

Based on my analysis: the paper has a genuinely interesting empirical finding (the sub-1B safety collapse) but is undermined by (a) a confounded experimental design for its central comparative claim, and (b) completely undefined methodology for its claimed core contribution (the Collapse Analysis metrics). The safety collapse finding is potentially salvageable if the metrics are documented, but the paper as written does not allow verification of its most interesting result. The confound in the LM comparison is structural and would require either re-running experiments or significantly reframing claims.

Against ICLR standards: the paper presents empirical results that are interesting but cannot be adequately evaluated because key methodology is unreported, and the headline comparison is confounded. This places it in the reject range.

MY FINAL SCORE: <score>3</score>
MY FINAL DECISION: <decision>Reject</decision>